VLST Corporation Announces Board and Executive Management Ap... (Leukine(R)) andTNF-receptor (Enbrel(R))....)

VLST Corporation Announces Board and Executive Management Appointments

Date:2/13/2008

Leukine(R)) and TNF-receptor (Enbrel(R)). Dr. Urdal has served as a director of Dendreon since 1995 and also serves as director for Ore Pharmaceuticals, Inc. Dr. Urdal received his M.S. in Public Health and his Ph.D. in Biochemical Oncology from the University of Washington.

Mr. Myers has broad experience in M&A, licensing, litigation and intellectual property, including more than 16 years experience in intellectual property acquisition, enforcement and defense in the biotech and pharmaceutical fields. Mr. Myers joined Corixa in 2004 and served as associate general counsel, intellectual property. In 2005, Corixa was acquired by GlaxoSmithKline, plc., during which time Mr. Myers played a key role in the transition of assets. Mr. Myers also served as senior patent counsel to Pfizer Inc., where his responsibilities included global management of Pfizer's antiviral therapeutic portfolio, as well as patent enforcement and defense in the US, Canada, Asia and Japan. Prior to his in-house work, Mr. Myers served as outside counsel to several Fortune 500 companies. Mr. Myers received an M.S. in Molecular Pharmacology from Thomas Jefferson University in Philadelphia, PA and his J.D. from George Washington University in Washington, DC.

VLST recently relocated its operations within Seattle to a new corporate headquarters at 307 Westlake Avenue North. The new office location provides for expanded laboratory and research facilities.

About VLST

VLST Corporation is a privately held biotechnology company dedicated to the streamlined discovery and development of novel therapeutics for the treatment of inflammatory and autoimmune disorders. The VLST approach combines novel bioinformatics and cutting-edge proteomics to provide a rapid and rational approach to identifying new targets for the development of novel biologic therapies. The VLST discovery platform has primary applications for the treatment of rheumatoid arthritis, Crohn's disease, multiple sclerosis
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
2. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
3. LifeCell Corporation Revises Full Year 2007 Preliminary Results and Schedules Fourth Quarter 2007 Financial Results Conference Call; February 27, 2008 at 10:00 a.m. Eastern
4. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
5. Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy
6. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
7. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
8. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
9. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
10. DURECT Corporation Invites You to Join Its Fourth Quarter 2007 Earnings Conference Call
11. Baxa Corporation Launches New Web Site

Post Your Comments:

VLST Corporation Announces Board and Executive Management Ap...(Leukine(R)) andTNF-receptor (Enbrel(R))....)